Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Concentra Group Holdings Parent, Inc. stock logo
CON
Concentra Group Holdings Parent
$24.98
+0.9%
$23.44
$18.55
$26.66
$3.17B0.82977,869 shs747,399 shs
Omada Health, Inc. stock logo
OMDA
Omada Health
$18.21
+5.1%
$14.73
$10.28
$28.40
$1.03BN/A1.30 million shs969,137 shs
Option Care Health, Inc. stock logo
OPCH
Option Care Health
$20.07
-2.2%
$24.48
$18.01
$36.80
$3.22B0.673.55 million shs2.51 million shs
Veracyte, Inc. stock logo
VCYT
Veracyte
$49.94
+2.6%
$37.48
$22.61
$50.71
$3.89B1.981.13 million shs1.64 million shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Concentra Group Holdings Parent, Inc. stock logo
CON
Concentra Group Holdings Parent
+0.66%-1.59%+9.46%+9.57%+15.82%
Omada Health, Inc. stock logo
OMDA
Omada Health
+5.08%+2.19%+16.36%+29.61%+1,820,999,900.00%
Option Care Health, Inc. stock logo
OPCH
Option Care Health
-2.24%-7.00%-5.77%-32.74%-35.90%
Veracyte, Inc. stock logo
VCYT
Veracyte
+2.57%+4.06%+51.47%+47.53%+83.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Concentra Group Holdings Parent, Inc. stock logo
CON
Concentra Group Holdings Parent
$24.98
+0.9%
$23.44
$18.55
$26.66
$3.17B0.82977,869 shs747,399 shs
Omada Health, Inc. stock logo
OMDA
Omada Health
$18.21
+5.1%
$14.73
$10.28
$28.40
$1.03BN/A1.30 million shs969,137 shs
Option Care Health, Inc. stock logo
OPCH
Option Care Health
$20.07
-2.2%
$24.48
$18.01
$36.80
$3.22B0.673.55 million shs2.51 million shs
Veracyte, Inc. stock logo
VCYT
Veracyte
$49.94
+2.6%
$37.48
$22.61
$50.71
$3.89B1.981.13 million shs1.64 million shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Concentra Group Holdings Parent, Inc. stock logo
CON
Concentra Group Holdings Parent
+0.66%-1.59%+9.46%+9.57%+15.82%
Omada Health, Inc. stock logo
OMDA
Omada Health
+5.08%+2.19%+16.36%+29.61%+1,820,999,900.00%
Option Care Health, Inc. stock logo
OPCH
Option Care Health
-2.24%-7.00%-5.77%-32.74%-35.90%
Veracyte, Inc. stock logo
VCYT
Veracyte
+2.57%+4.06%+51.47%+47.53%+83.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Concentra Group Holdings Parent, Inc. stock logo
CON
Concentra Group Holdings Parent
2.83
Moderate Buy$30.2521.08% Upside
Omada Health, Inc. stock logo
OMDA
Omada Health
2.69
Moderate Buy$22.9125.81% Upside
Option Care Health, Inc. stock logo
OPCH
Option Care Health
2.69
Moderate Buy$31.2555.71% Upside
Veracyte, Inc. stock logo
VCYT
Veracyte
2.56
Moderate Buy$47.57-4.74% Downside

Current Analyst Ratings Breakdown

Latest OMDA, VCYT, OPCH, and CON Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/2/2026
Veracyte, Inc. stock logo
VCYT
Veracyte
Initiated CoverageOutperform$55.00
6/1/2026
Veracyte, Inc. stock logo
VCYT
Veracyte
Boost Price TargetBuy$48.00 ➝ $57.00
6/1/2026
Veracyte, Inc. stock logo
VCYT
Veracyte
UpgradeStrong-Buy
5/28/2026
Veracyte, Inc. stock logo
VCYT
Veracyte
Reiterated RatingBuy$48.00
5/11/2026
Concentra Group Holdings Parent, Inc. stock logo
CON
Concentra Group Holdings Parent
UpgradeHold (C+)Buy (B-)
5/11/2026
Option Care Health, Inc. stock logo
OPCH
Option Care Health
DowngradeHold (C)Hold (C-)
5/11/2026
Concentra Group Holdings Parent, Inc. stock logo
CON
Concentra Group Holdings Parent
Reiterated RatingBuy$29.00 ➝ $31.00
5/11/2026
Option Care Health, Inc. stock logo
OPCH
Option Care Health
DowngradeHoldStrong Sell
5/8/2026
Omada Health, Inc. stock logo
OMDA
Omada Health
Reiterated RatingBuy
5/8/2026
Omada Health, Inc. stock logo
OMDA
Omada Health
Reiterated RatingOutperform$20.00
5/8/2026
Omada Health, Inc. stock logo
OMDA
Omada Health
Set Price Target$24.00
(Data available from 6/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Concentra Group Holdings Parent, Inc. stock logo
CON
Concentra Group Holdings Parent
$2.23B1.43$2.01 per share12.40$3.13 per share7.98
Omada Health, Inc. stock logo
OMDA
Omada Health
$260.21M4.16N/AN/A$3.97 per share4.59
Option Care Health, Inc. stock logo
OPCH
Option Care Health
$5.67B0.56$2.00 per share10.05$8.36 per share2.40
Veracyte, Inc. stock logo
VCYT
Veracyte
$541.74M7.36$1.53 per share32.69$16.57 per share3.01
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Concentra Group Holdings Parent, Inc. stock logo
CON
Concentra Group Holdings Parent
$166.41M$1.3917.9714.441.127.97%47.14%6.48%8/6/2026 (Estimated)
Omada Health, Inc. stock logo
OMDA
Omada Health
-$12.78M-$0.27N/A130.07N/A-2.22%-1.82%-1.36%N/A
Option Care Health, Inc. stock logo
OPCH
Option Care Health
$207.59M$1.2915.5610.911.143.64%18.17%7.16%7/29/2026 (Estimated)
Veracyte, Inc. stock logo
VCYT
Veracyte
$66.35M$1.0945.8235.17N/A16.25%9.07%8.38%8/5/2026 (Estimated)

Latest OMDA, VCYT, OPCH, and CON Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2026Q1 2026
Concentra Group Holdings Parent, Inc. stock logo
CON
Concentra Group Holdings Parent
$0.35$0.40+$0.05$0.39$553.53 million$569.56 million
5/7/2026Q1 2026
Omada Health, Inc. stock logo
OMDA
Omada Health
-$0.08-$0.05+$0.03-$0.05N/A$78.05 million
5/5/2026Q1 2026
Veracyte, Inc. stock logo
VCYT
Veracyte
$0.34$0.52+$0.18$0.35$130.36 million$139.07 million
4/30/2026Q1 2026
Option Care Health, Inc. stock logo
OPCH
Option Care Health
$0.37$0.40+$0.03$0.29$1.39 billion$1.35 billion
3/5/2026Q4 2025
Omada Health, Inc. stock logo
OMDA
Omada Health
-$0.04$0.08+$0.12$0.08N/A$75.85 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Concentra Group Holdings Parent, Inc. stock logo
CON
Concentra Group Holdings Parent
$0.251.00%N/A17.99%N/A
Omada Health, Inc. stock logo
OMDA
Omada Health
N/AN/AN/AN/AN/A
Option Care Health, Inc. stock logo
OPCH
Option Care Health
N/AN/AN/AN/AN/A
Veracyte, Inc. stock logo
VCYT
Veracyte
N/AN/AN/AN/AN/A

Latest OMDA, VCYT, OPCH, and CON Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/5/2026
Concentra Group Holdings Parent, Inc. stock logo
CON
Concentra Group Holdings Parent
quarterly$0.06250.98%5/19/20265/19/20266/9/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Concentra Group Holdings Parent, Inc. stock logo
CON
Concentra Group Holdings Parent
3.62
1.26
1.26
Omada Health, Inc. stock logo
OMDA
Omada Health
N/A
3.92
3.87
Option Care Health, Inc. stock logo
OPCH
Option Care Health
0.85
1.64
1.07
Veracyte, Inc. stock logo
VCYT
Veracyte
N/A
9.31
8.92

Institutional Ownership

CompanyInstitutional Ownership
Concentra Group Holdings Parent, Inc. stock logo
CON
Concentra Group Holdings Parent
N/A
Omada Health, Inc. stock logo
OMDA
Omada Health
N/A
Option Care Health, Inc. stock logo
OPCH
Option Care Health
98.05%
Veracyte, Inc. stock logo
VCYT
Veracyte
N/A

Insider Ownership

CompanyInsider Ownership
Concentra Group Holdings Parent, Inc. stock logo
CON
Concentra Group Holdings Parent
8.10%
Omada Health, Inc. stock logo
OMDA
Omada Health
6.38%
Option Care Health, Inc. stock logo
OPCH
Option Care Health
1.70%
Veracyte, Inc. stock logo
VCYT
Veracyte
1.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Concentra Group Holdings Parent, Inc. stock logo
CON
Concentra Group Holdings Parent
13,133127.96 million117.60 millionN/A
Omada Health, Inc. stock logo
OMDA
Omada Health
84959.45 million55.66 millionN/A
Option Care Health, Inc. stock logo
OPCH
Option Care Health
8,266157.03 million154.36 millionOptionable
Veracyte, Inc. stock logo
VCYT
Veracyte
79079.79 million78.68 millionOptionable

Recent News About These Companies

Veracyte (NASDAQ:VCYT) CFO Sells $177,088.53 in Stock
Canaccord Genuity Reaffirms Their Hold Rating on Veracyte (VCYT)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Concentra Group Holdings Parent stock logo

Concentra Group Holdings Parent NYSE:CON

$24.98 +0.23 (+0.94%)
Closing price 06/4/2026 03:59 PM Eastern
Extended Trading
$25.22 +0.24 (+0.95%)
As of 07:07 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Concentra Group Holdings Parent, Inc. provides occupational health services in the United States. The company offers occupational and consumer health services, including workers' compensation injury care, urgent care, clinical testing, preventative care, and employer services, as well as wellness programs through occupational health centers and onsite clinics. It also provides Concentra Telemed, a telemedicine solution for the treatment of work-related injuries and illnesses, and employer services; pharmacy solution under the Concentra Pharmacy name; and Concentra Medical Compliance Administration, a third-party administrator that helps to manage abuse testing programs for employers with regulated or non-regulated workforces. The company was founded in 1979 and is based in Mechanicsburg, Pennsylvania. Concentra Group Holdings Parent, Inc. is a subsidiary of Select Medical Corporation.

Omada Health stock logo

Omada Health NASDAQ:OMDA

$18.21 +0.88 (+5.08%)
Closing price 06/4/2026 04:00 PM Eastern
Extended Trading
$18.14 -0.07 (-0.37%)
As of 06:52 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Omada’s mission is to bend the curve. Our hope is that, one day, tomorrow’s epidemiologists will notice a bend in disease curves, wonder what might be happening, and conclude that part of that impact has been Omada. As part of that mission, we strive to inspire and enable people to make lasting health changes on their own terms. We deliver virtual care between doctor’s visits, providing an engaging, personalized, and integrated experience for our members that is designed to improve their health while delivering value for the employers, health plans, health systems, pharmacy benefit managers (“PBMs”), and other entities that cover the cost of our programs. As of 2022, more than 156 million Americans suffered from one or more chronic conditions, such as obesity, prediabetes, diabetes, hypertension, and musculoskeletal (“MSK”) conditions, and approximately 40% of U.S. adults suffered from two or more chronic conditions, based on data published in the Annals of Bioethics & Clinical Applications. Managing these conditions—and treating the acute problems they can lead to—creates significant costs for employers, health plans, PBMs, and other entities that pay for the cost of care. According to the American Diabetes Association (the “ADA”)’s report “Economic Costs of Diabetes in the U.S. in 2022,” chronic diseases were the leading driver of U.S. medical spend, with diabetes alone accounting for $1 out of every $7 spent. According to research published in Diabetes Care, in 2022, an employee with type 2 diabetes cost on average an additional $7,000 annually due to increased medical costs, absenteeism, and lost productivity. The direct medical cost of people living with diabetes increased by 35% from 2012 to 2022, despite stable diabetes prevalence. It doesn’t have to be that way. Many chronic conditions can be managed or prevented at a more reasonable cost. One reason these conditions are often not managed efficiently is that the U.S. healthcare system was built mainly on encounter-based reimbursement models that pay for specific services, primarily as issues arise. Between what can be short and infrequent office visits, patients are often left to manage their condition on their own. Many have a hard time sticking to care plans and health goals—losing weight, eating better, exercising more—and have few resources to turn to for ongoing questions, accountability, and support as they work to change their lifestyle. Behavior change is hard. Omada was created to make it easier. Our virtual care programs are rooted in evidence and combine relationship-based, human-led clinical care with purpose-built technology. We call this approach Compassionate Intelligence. We work to develop trust with each member and use technology to help us personalize their experience, enabling us to unlock results at scale. We sell our programs to customers that cover the cost for covered individuals. Our customers include employers that cover our programs for their employees and their dependents, health systems that cover our programs for patients, and any other entity that is financially responsible for costs of our programs for a population of covered lives. We also work closely with health plans and PBMs that either cover our programs for a portion of their members as our customers or act as channel partners reselling our programs to their own end customers. Our channel partners’ end customers typically consist of employers that cover our programs for their employees and their dependents. In general, our customers cover the cost of our programs for our members, except that members in our physical therapy program may incur copays, coinsurance, or deductibles, depending on plan design, much like in-person physical therapy. We launched our initial program in diabetes prevention and weight health in 2012, with the goal of showing that a virtual program could achieve the same clinical results as its in-person archetype. Through feedback from our customers, channel partners, members, and the market at large, we then recognized the need to create an integrated, multi-condition care platform to address multiple, commonly comorbid, chronic conditions. Today, we offer cardiometabolic programs for prediabetes, diabetes, and hypertension; a physical therapy program to address MSK conditions; additional support for members taking glucagon-like peptide-1 agonists (“GLP-1”) in our cardiometabolic programs (“GLP-1 Care Tracks”); and behavioral health support across all programs. Since our founding, our programs have had a meaningful, positive impact. As of March 31, 2025, we had more than 2,000 customers and over 679,000 total members enrolled in one or more programs, and we had supported over one million members since launch. We count a member as enrolled in a program to the extent their participation was billed at least once in the preceding 12 months. We believe our programs serve a clear need for our customers and channel partners as well as our members, which is reinforced by our strong customer satisfaction and member engagement rates. In 2024, our average customer satisfaction rate for the year was over 90% for each of program implementation and customer success. Our customer satisfaction rate is based on survey results from customers that launched a new program during the measured period, and we consider a customer to be satisfied if they rated our program implementation and ongoing customer success, as applicable, at a 5 or higher on a 7-point scale. We believe that our customer satisfaction rates are strong and reflect the value of our services to customers. In 2024, more than 55% of members still engaged with our cardiometabolic programs at least once per month after a year in the program, and over 50% still engaged monthly after two years. We consider members to be still engaged after one year or two years in the program if, during their twelfth or twenty-fourth month of program participation in a cardiometabolic program, they complete at least one interaction with us, such as logging in or interacting with the Omada mobile app, sending messages to Omada Care Team members, or recording metrics such as weight, blood pressure, or blood glucose values. On average, in 2024, members in a cardiometabolic program engaged more than 30 times per month throughout their first year. Based on our experience and feedback from customers, we believe these engagement rates to be positive and to demonstrate the attractiveness of our program to members. We are proud of our progress, and we are just getting started. We have experienced strong growth since our inception. Revenue increased by 38% from $122.8 million to $169.8 million for the years ended December 31, 2023 and 2024, respectively, and by 57% from $35.1 million to $55.0 million for the three months ended March 31, 2024 and 2025, respectively. We continue to generate revenue from recurring customers, as evidenced by our net dollar retention rate, which for customers who were contracted as of the beginning of the prior period, is calculated as total billings generated in a particular period divided by total billings generated in the prior period and was 110% and 128% for the years ended December 31, 2023 and 2024, respectively. We have a history of net losses, due in part to the significant investments we have made in the design and development of our programs and platform enhancements, and have not yet achieved profitability on an annual basis. Our principal executive offices are located San Francisco, California.

Option Care Health stock logo

Option Care Health NASDAQ:OPCH

$20.07 -0.46 (-2.24%)
Closing price 06/4/2026 04:00 PM Eastern
Extended Trading
$19.91 -0.16 (-0.79%)
As of 07:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Option Care Health, Inc. offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders. It also offers treatments to manage the progression of neurological disorders, such as multiple sclerosis, duchenne muscular dystrophy, and other neurological disorder; infusion therapies for bleeding disorders, such as hemophilia and von Willebrand diseases; therapies for women with high-risk pregnancies; and other infusion therapies to treat various conditions, including pain management, chemotherapy, and respiratory medications, as well as nursing services. The company markets its services through patient referrals, including physicians, hospital discharge planners, hospital personnel, health maintenance organizations, and preferred provider organizations. Option Care Health, Inc. is headquartered in Bannockburn, Illinois.

Veracyte stock logo

Veracyte NASDAQ:VCYT

$49.94 +1.25 (+2.57%)
Closing price 06/4/2026 04:00 PM Eastern
Extended Trading
$49.75 -0.19 (-0.38%)
As of 07:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.